IP Library Granted Patent US 11,154,481
Granted Patent B2
US 11,154,481 · App. 16/583,421 · Granted Oct 26, 2021

Hyaluronic acid composition

Inventors: Åsa Wiebensjö (Uppsala, SE); Katarina Edsman (Uppsala, SE)
Assignee: Q-MED AB
A61K8/602A61K8/42A61K8/676A61K8/735A61K31/167A61K31/245A61K31/375A61K31/445A61K31/728A61K45/06A61K47/24A61K47/61A61L27/20A61L27/54A61L31/042A61L31/16A61Q7/00A61Q19/004A61Q19/007A61Q19/08A61K9/0019A61K47/22A61K47/36A61K2800/91A61L2300/402A61L2400/06A61L2400/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,481
App. No.
16/583,421
Granted
Oct 26, 2021
Kind
B2
Abstract

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

Claims (13)

1. A sterilized injectable hyaluronic acid composition, comprising: a hyaluronic acid gel,

a therapeutically relevant concentration of lidocaine, and an ascorbic acid derivative selected from the group consisting of ascorbyl phosphates, ascorbyl sulfates, and ascorbyl glycosides, in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the lidocaine upon sterilization by heat, wherein the lidocaine is present in a concentration in the range of 1 to 5 mg/ml, wherein the concentration of the ascorbic acid derivative in the composition is in the range of 0.01 to 5 mg/ml, and the composition has been subjected to sterilization by autoclaving at a F0-value≥4, wherein the hyaluronic acid gel is crosslinked by modification with a chemical crosslinking agent, wherein a degree of modification of the hyaluronic acid gel is less than 2 mol %, and wherein the hyaluronic acid composition does not exhibit increased stability compared to the same composition without an ascorbic acid derivative.

2. The injectable hyaluronic acid composition according to claim 1 , wherein the ascorbic acid derivative is selected from the group consisting of ascorbyl phosphates and ascorbyl glycosides, or a combination thereof.

3. The injectable hyaluronic acid composition according to claim 2 , wherein the ascorbic acid derivative is an ascorbyl glycoside.

4. The injectable hyaluronic acid composition according to claim 2 , wherein the ascorbic acid derivative is ascorbyl glucoside.

5. The injectable hyaluronic acid composition according to claim 1 , wherein the concentration of the ascorbic acid derivative is in the range of 0.01 to 0.5 mg/ml.

6. The injectable hyaluronic acid composition according to claim 2 , wherein the ascorbic acid derivative is selected from the group consisting of sodium ascorbyl phosphate (SAP) and magnesium ascorbyl phosphate (MAP).

7. The injectable hyaluronic acid composition according to claim 6 , wherein the concentration of the sodium ascorbyl phosphate (SAP) or magnesium ascorbyl phosphate (MAP) is in the range of 0.01 to 1 mg/ml.

8. The injectable hyaluronic acid composition according to claim 7 , wherein the concentration of the sodium ascorbyl phosphate (SAP) or magnesium ascorbyl phosphate (MAP) is in the range of 0.01 to 0.5 mg/ml.

9. The injectable hyaluronic acid composition according to claim 4 , wherein the concentration of the ascorbyl glucoside is in the range of 0.01 to 1 mg/ml.

10. The injectable hyaluronic acid composition according to claim 9 , wherein the concentration of the ascorbyl glucoside is in the range of 0.01 to 0.8 mg/ml.

11. The injectable hyaluronic acid composition according to claim 10 , wherein the concentration of the ascorbyl glucoside is in the range of 0.05 to 0.4 mg/ml.

12. A medicament comprising the injectable hyaluronic acid composition according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2023
From: Q-MED AB
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 062694/0694 →
CHANGE OF NAME Recorded Feb 14, 2023
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 062696/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2019
From: WIEBENSJÖ, ÅSA; EDSMAN, KATARINA
To: Q-MED AB
Reel/Frame 050498/0272 →
Priority Claims (1)
EP 11153232 · Feb 3, 2011 · regional
Continuity (3)
Continuation 16126268 · Sep 10, 2018
Division 13983448
Related Publication 20200261343A1 · Aug 20, 2020